Sumitomo completes sale of $648 million of Common Shares of Roivant Sciences Ltd.
Client(s) Sumitomo Pharma Co., Ltd.
Jones Day represented Sumitomo Pharma Co., Ltd. in connection with its privately negotiated sale of $648 million of Common Shares of Roivant Sciences Ltd.